Consequently, we aimed to conduct a nationwide study (ARISE study) with a sufficient number of lung adenocarcinoma patients who progressed with each of the three EGFR-TKI therapies and to investigate the association between prior EGFR-TKI treatment and the incidence of acquired T790M-associated resistance. Here, EGFR is linked to lung adenocarcinoma.